Market revenue in 2023 | USD 184.2 million |
Market revenue in 2030 | USD 960.7 million |
Growth rate | 26.6% (CAGR from 2023 to 2030) |
Largest segment | Pre-clinical |
Fastest growing segment | Pre-clinical |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pre-clinical, Clinical |
Key market players worldwide | Lonza Group Ltd, Catalent Inc, Cytiva, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, Novartis AG ADR, Wuxi AppTec Co Ltd, AGC Inc, OmniAb Inc, Rentschler Biopharma SE, Charles River Laboratories International Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy cdmo market will help companies and investors design strategic landscapes.
Pre-clinical was the largest segment with a revenue share of 66.18% in 2023. Horizon Databook has segmented the Latin America cell and gene therapy cdmo market based on pre-clinical, clinical covering the revenue growth of each sub-segment from 2018 to 2030.
The increasing demand for pharmaceutical drugs drives the Latin America cell and gene therapy CDMO market as pharmaceutical companies invest in R&D. Furthermore, the growing number of clinical trials and the burden of diseases drive expansion in the Latin America market.
In addition, the Latin America market is expected to grow rapidly, driven by the affordability of services offered by its CDMOs and the increasing participation of emerging regional players in the pharmaceutical & biotechnology industries.
For instance, in December 2023, Acino, a pharmaceutical company based in Zurich, acquired M8 Pharmaceuticals, a biopharmaceutical company based in Mexico City. This acquisition allows Acino to expand into two largest pharmaceutical markets in Latin America, strengthening its presence in the region and enhancing its offerings for healthcare professionals & patients.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America cell and gene therapy cdmo market , including forecasts for subscribers. This continent databook contains high-level insights into Latin America cell and gene therapy cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account